Kim Reiss, MD, an assistant professor of Hematology-Oncology in Penn’s Perelman College of Drugs and the examine’s lead creator. Credit score: Penn Drugs

Greater than two-thirds of pancreatic most cancers sufferers harboring genetic mutations noticed their tumor cease rising or shrink considerably after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as a upkeep remedy, researchers from the Abramson Most cancers Middle (ACC) on the College of Pennsylvania reported on-line at this time within the Journal of Scientific Oncology. The outcomes from the part II trial on the ACC help the use rucaparib for pancreatic most cancers